her glp-1 Agonist Scripts Jumped 600% for Teens, Young Adults Since 2020 GLP-1 Weight Loss Semaglutide in

Tirzepatide produced a 21% average weight reduction in non-diabetics and was FDA approved for weight loss in 2023

Its dangerous

Cell-based assays for Gs-protein (cAMP production), Gq-protein (intracellular Ca 2+ mobilization) and -arrestin (1 and 2) signalling were used to determine the potency (EC 50

Emerging Players 3

"The FDA supports development of complex generic drugs, such as GLP-1s, by funding research and informing industry through guidance as part of our ongoing efforts to increase access to needed medications

Fatigue is listed as a common adverse reaction (occurring in 5% of patients) in the FDA prescribing information for both Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide), and occurred more frequently than with placebo in clinical trials